Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SLC9A1 | P19634 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SLC9A5 | Q14940 | 10/20 | 0.72 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-(N-Methyl-N-Isobutyl)Amiloride SCHEMBL9852472 | 1.00 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14513859 | 0.86 | SLC9A5 (0.77) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14504165 | 0.84 | SLC9A5 (0.73) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL2432734 | 0.83 | CYP1A2 (0.70) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL29406659 | 0.83 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL9852481 | 0.83 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL2431417 | 0.81 | CYP1A2 (0.67) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| 5-(N-Ethyl-N-Isopropyl)Amiloride SCHEMBL29404178 | 0.80 | SLC9A5 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| 5-(N-Ethyl-N-Isopropyl)Amiloride SCHEMBL9852524 | 0.80 | SLC9A5 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14504168 | 0.79 | CYP1A2 (0.77) | CYP1A2TSHRSLC9A1CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| WO-2023229993-A1 | OPHTHALMIC FORMULATION CAPABLE OF DELIVERING METFORMIN TO CHOROID RPE AND RETINA | CURATIVE BIOTECHNOLOGY, INC. (US) | 2023-11-30 | — | — | WO | claimed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | claimed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | claimed |
| CN-109475552-B | Methods and compositions for appetite control and weight management | 上海药苑生物科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| US-12601000-B2 | Method for the hydroxylation of steroids | ANNIKKI GMBH (AT) | 2026-04-14 | — | — | US | disclosed |
| EP-4680243-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| US-20250162982-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | INSMED INCORPORATED (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2024196814-A1 | METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-26 | — | — | WO | disclosed |
| EP-4027985-A1 | DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114650813-A | Druggable targets for the treatment of retinal degeneration | 美国卫生和人力服务部 | 2022-06-21 | — | — | CN | disclosed |
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | BIOPHARMA CREDIT PLC (GB) | 2022-05-05 | — | — | US | disclosed |
| CN-109475552-B | Methods and compositions for appetite control and weight management | 上海药苑生物科技有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11279784-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| WO-2022043343-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | FONDATION ESPERARE (CH) | 2022-03-03 | — | — | WO | disclosed |
| EP-3960165-A1 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Fondation EspeRare (CH) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279784-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | NISCH, TPO, UGT1A9 | CYP1A2 606/4885TSHR 150/4885SLC9A1 1516/4885 |
| US-20220135513-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, PTGER1, PTGIR | CYP1A2 567/4885TSHR 714/4885SLC9A1 2034/4885 |
| US-12601000-B2 | Method for the hydroxylation of steroids | CYP11B1, CYP11B2, CYP11A1 | CYP1A2 65/4885TSHR 1382/4885SLC9A1 2808/4885 |
| US-20250162982-A1 | METHODS OF MANUFACTURING TREPROSTINIL AND TREPROSTINIL DERIVATIVE PRODRUGS | PTGIS, PTGER1, PTGIR | CYP1A2 567/4885TSHR 714/4885SLC9A1 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.